Rethinking child treatments

Developing evidence-based treatments - specifically for children

Releases

Releases

21. September, 2023

Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001

Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of...

Read more

Releases

12. September, 2023

Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children

On 12 September – Cessatech A/S (“Cessatech” or “the Company”) announces that EMA’s Paediatric...

Read more

Releases

24. August, 2023

Second quarter report Q2-2023

US co-development and commercialization partnership signed for CT001 – potential income already from 2024...

Read more

Releases

27. June, 2023

Cessatech and Ventis Pharma announce US partnership for CT001

On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...

Read more

Facts about Children

Facts

31. August, 2023

August business update

  A short update to the great progress we continue to make….thanks for reading!...

Read more

Facts

25. August, 2023

New findings supporting CT001

Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...

Read more

Facts

15. March, 2022

Off-label use of medication in children continue to be the rule rather than the exception…

A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...

Read more

Facts

3. March, 2022

Physical restraint of children in 79% of Scandinavian emergency departments

Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...

Read more

Facts

2. February, 2021

Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner

Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...

Read more

Experience

Proven track-record within drug development and product launches, in Europe, US and Asia.

The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.

Team
Lead Asset

CT001 – Nasal spray

Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.

See details

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.